Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

NIVOREN: Nivolumab in a 'real world setting' for metastatic clear-cell renal cell carcinoma

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 18.02.20
Views: 129
Rating:

Dr Yann-Alexandre Vano - Hôpital Européen Georges-Pompidou, Paris, France

Dr Yann-Alexandre Vano speaks to ecancer at the 2020 ASCO GU meeting at San Francisco about the NIVOREN study.

The NIVOREN GETUG-AFU 26 study reported safety and efficacy of nivolumab for patients with metastatic clear-cell renal cell carcinoma (mccRCC) in a “real world setting”.

Dr Vano outlines the results which give correlations for outcomes with nivolumab.

He outlines the way this study can be adapted in the future, and when can be learnt from these initial exploratory results.

Related videos

follow us

WIN 2020


Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation